Benzinga | May 10, 2021 06:32AM EDT

Fortress Biotech Enters a License Agreement with Fuji Yakuhin to Develop Dotinurad in the United State, UK, European Union and Canada

Dotinurad (URECE(r) tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia